{rfName}
Ph

Indexed in

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Alvarez-Larran, AAuthor

Share

July 25, 2024
Publications
>
Article

Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis

Publicated to: Future Oncology. 18 (27): 2987-2997 - 2022-09-01 18(27), DOI: 10.2217/fon-2022-0484

Authors:

Harrison, CN; Gupta, VK; Gerds, AT; Rampal, R; Verstovsek, S; Talpaz, M; Kiladjian, JJ; Mesa, R; Kuykendall, AT; Vannucchi, AM; Palandri, F; Grosicki, S; Devos, T; Jourdan, E; Wondergem, MJ; Al-Ali, HK; Buxhofer-Ausch, V; Alvarez-Larrán, A; Patriarca, A; Kremyanskaya, M; Mead, AJ; Akhani, S; Sheikine, Y; Colak, G; Mascarenhas, J
[+]

Affiliations

Amsterdam Univ Med Ctr, Dept Hematol - Author
Azienda Osped Univ Careggi, Dept Hematol - Author
Azienda Osped Univ Maggiore Carita Novara, Hematol Unit - Author
CHU, Dept Hematol - Author
Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol - Author
Constellat Pharmaceut Inc - Author
Guys & St Thomas NHS Fdn Trust, Guys Hosp - Author
H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol - Author
Hop St Louis - Author
Hosp Clin Barcelona, Dept Hematol - Author
Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Oncol - Author
IRCCS Azienda Osped Univ S Orsola Malpighi, Dept Hematol - Author
Johannes Kepler Univ Linz - Author
Katholieke Univ Leuven, Rega Inst, Lab Mol Immunol - Author
Med Univ Silesia, Dept Hematol & Canc Prevent - Author
Mem Sloan Kettering Canc Ctr, Ctr Hematol Malignancies - Author
MorphoSys AG - Author
Univ Hosp Halle, Krukenberg Canc Ctr - Author
Univ Michigan, Div Hematol Oncol - Author
Univ Oxford, John Radcliffe Hosp, MRC Weatherall Inst Mol Med, MRC Mol Haematol Unit - Author
Univ Texas MD Anderson Canc Ctr, Dept Leukemia - Author
Univ Toronto, Princess Margaret Canc Ctr, Dept Med, Toronto - Author
UT Hlth San Antonio Canc Ctr, Mays Canc Ctr - Author
See more

Abstract

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm, typically associated with disease-related symptoms, splenomegaly, cytopenias and bone marrow fibrosis. Patients experience a significant symptom burden and a reduced life expectancy. Patients with MF receive ruxolitinib as the current standard of care, but the depth and durability of responses and the percentage of patients achieving clinical outcome measures are limited; thus, a significant unmet medical need exists. Pelabresib is an investigational small-molecule bromodomain and extraterminal domain inhibitor currently in clinical development for MF. The aim of this article is to describe the design of the ongoing, global, phase III, double-blind, placebocontrolled MANIFEST-2 study evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with JAKi treatment-naive MF. Plain language summary: Myelofibrosis (MF) is a rare type of blood cancer that interferes with the process of blood cell production by the bone marrow. In patients with MF, the bone marrow becomes overactive, leading to scarring and subsequently a lack of healthy blood cells being produced. The main symptoms of MF include anemia, fatigue, weakness and pain or discomfort in the abdomen. MF is associated with a shortened life expectancy. The current go-to treatment for MF is ruxolitinib. However, ruxolitinib has shown limited efficacy in improving clinical symptoms long term; so, new safe and effective treatments are needed. Pelabresib is a novel drug currently in clinical development for treating MF. The aim of this article is to describe the design of the ongoing, global phase III MANIFEST-2 study. MANIFEST-2 is evaluating the efficacy and safety of pelabresib and ruxolitinib versus placebo and ruxolitinib in patients with MF. [GRAPHICS] .
[+]

Keywords

Antineoplastic agentAntineoplastic agentsAntineoplastic combined chemotherapy protocolsArticleBlood cell countBone marrow biopsyBromodomainClinical outcomeClinical trials, phase iii as topicComplicationComputer assisted tomographyControlled studyCpi-0610DiscontinuationDisease exacerbationDouble blind procedureEcog performance statusEfficacyFollow upHematopoietic stem cell transplantationHumanHumansJaki treatment-naiveJanus kinase inhibitorJanus kinase inhibitorsLife expectancyMajor clinical studyManifest-2MomelotinibMulticenter studyMyelofibrosisMyeloid metaplasiaNitrileNitrilesOutcomesOverall survivalPelabresibPhase 3 clinical trialPlaceboPlatelet countPolycythemia veraPrimary myelofibrosisProgression free survivalPyrazole derivativePyrazolesPyrimidine derivativePyrimidinesRandomized controlled trialRandomized controlled trial (topic)Randomized controlled trials as topicRisk factorRuxolitinibSafetyScoring systemThrombocythemiaTreatment outcomeTrial

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Future Oncology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.87. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 2.48 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-04, the following number of citations:

  • WoS: 30
  • Scopus: 31
  • Europe PMC: 10
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 42.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 41 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 38.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 9 (Altmetric).
  • The number of mentions in news outlets: 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Austria; Belgium; Canada; France; Germany; Italy; Mali; Netherlands; Poland; United Kingdom; United States of America.

[+]